Citius pharmaceuticals resubmits the biologics license application of lymphir™ (denileukin diftitox) for the treatment of adults with relapsed or refractory cutaneous t-cell lymphoma

Fda acceptance of the completed resubmission package and issuance of a prescription drug user fee act (pdufa) date is expected within 30 days of resubmission cranford, n.j. , feb. 13, 2024 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today announced the resubmission of the company's biologics license application (bla) to the u.s. food and drug administration (fda) for lymphir™ (denileukin diftitox), an il-2-based immunotherapy for the treatment of patients with relapsed or refractory cutaneous t-cell lymphoma (ctcl) after at least one prior systemic therapy.
CTXR Ratings Summary
CTXR Quant Ranking